Peptide therapy is legal in the United States when prescribed by a licensed physician and dispensed by an FDA-registered compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This is not a gray area — it's the same regulatory framework that governs compounded hormone therapy, compounded antibiotics, and hundreds of other compounded medications used in legitimate medical practice every day.

The distinction that matters is pharmaceutical-grade vs. Research Use Only (RUO). Pharmaceutical-grade peptides from 503A/B compounders are subject to USP standards, purity testing, and COA documentation. RUO peptides sold by gray market vendors are not subject to any of this — they are manufactured and sold outside the prescription drug framework entirely.

503A Pharmacies compound for individual patients based on a valid prescription from a licensed practitioner. The relationship is patient-specific: the pharmacist is compounding a medication for a specific patient's needs that cannot be met by commercially available products. 503A pharmacies are regulated primarily by state boards of pharmacy with FDA oversight for specific conditions.

503B Outsourcing Facilities operate under direct FDA oversight and can produce larger batches of compounded drugs without patient-specific prescriptions. They sell to healthcare practitioners and facilities directly. 503B facilities must register with the FDA, comply with Current Good Manufacturing Practice (cGMP), and report adverse events. They are subject to FDA inspections.

All Peptide Pure products are sourced from 503A/B compliant compounders. Every batch ships with a Certificate of Analysis (COA) confirming purity, potency, and identity. This documentation is your compliance record.

The FDA categorizes bulk drug substances used in compounding. Category 1 substances are approved for use in compounding. Category 2 substances are under evaluation — they can be compounded while the FDA conducts its review, but reclassification to "not appropriate for compounding" (effectively Category 1 exclusion) can occur.

This is the primary regulatory risk in peptide compounding. When the FDA removes a substance from the Category 2 list, 503A/B pharmacies must stop compounding it. Practitioners who have been sourcing from pharmaceutical-grade 503A/B compounders with IRB documentation have a defensible record. Practitioners sourcing from gray market RUO suppliers simply stop, with no compliance documentation to fall back on.

The ONZEN IRB operates under Protocol PPRN-001-2025 / IRCM-2025-467, overseen by PI M. Scott Mortensen MD, MPAS, PA-C with Co-Investigators Dr. Shariar Cohen MD, Dr. Sunil Kurup MD, and Dr. Barbara Krutchkoff PhD.

IRB enrollment converts your clinical practice into a documented research framework. This creates three legally significant protections:

1. Documented ethical basis. The IRB review establishes that your protocols have been evaluated for safety and ethical appropriateness by an independent oversight committee. This is the standard defense against "practicing outside the standard of care" allegations for novel or investigational treatments.

2. Outcomes registry. Every enrolled patient's outcomes are documented in the PPRN registry. This builds the evidence base — over time, your practice generates the data that supports the protocols. Regulators and medical boards respond to data. Anecdote, however compelling, is not data.

3. Audit trail. If any protocol is ever scrutinized, you have a complete documented record: informed consent signed, IRB approval in place, pharmaceutical-grade sourcing with COA, and outcomes documented. The distinction between "systematically documenting outcomes from evidence-informed care" and "prescribing unapproved treatments without oversight" is entirely a paperwork distinction — and entirely within your control.

A Patient Membership Agreement (PMA) is a direct-pay concierge medicine model in which patients pay a membership fee for access to a physician's services, outside of insurance billing. PMAs are legal, increasingly common, and appropriate for concierge practices.

ONZEN does not operate a PMA. ONZEN is a clinical intelligence platform and IRB research consortium — not a membership medicine practice. Our reference page on PMAs is informational only, for practitioners who want to understand the model.

For PMA setup and compliance, we recommend mysafepma.com ↗ — the authoritative resource for PMA legal structuring.